Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UMG2-CD3
- Development stage
- Preclinical
- Lead developer
- University of Magna Graecia
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
UMG2-CD3 is a novel asymmetric (2+1) bispecific T-cell engager (BTCE) designed to target CD1a and CD3ε. Developed by researchers at Magna Græcia University with support from BiovelocITA, the antibody is constructed using knobs-into-holes technology. It incorporates a novel monoclonal antibody, UMG2, which binds to a previously uncharacterized epitope of CD1a, a glycoprotein highly expressed on cortical T-cell acute lymphoblastic leukemia (T-ALL) cells, healthy thymocytes, and Langerhans cells. By simultaneously binding CD1a on T-ALL cells and CD3ε on T-lymphocytes, UMG2-CD3 redirects T-cell-mediated cytotoxicity against leukemia cells, inducing T-cell activation, proliferation, and cytokine secretion. In preclinical studies, UMG2-CD3 demonstrated potent anti-tumor activity and significantly prolonged survival in humanized mouse models of T-ALL.
- Other names
- CD1a x CD3ε BTCECD1a-CD3εUMG2-BTCEUMG-2-BTCEUMG 2-BTCEUMG2/CD1a-CD3eUMG2/CD1a-CD3ε
02
Targets
CD1A (T-cell surface glycoprotein CD1a)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on UMG2-CD3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UMG2-CD3.